Your browser doesn't support javascript.
loading
Comparison of outcomes for Hispanic and non-Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma Database.
Guram, Kripa; Huang, Jiaming; Mouchati, Christian; Abdallah, Nour; Jani, Chinmay; Navani, Vishal; Xie, Wanling; El Zarif, Talal; Adib, Elio; Gebrael, Georges; Agarwal, Neeraj; Li, Haoran; Labaki, Chris; Labban, Muhieddine; Ruiz Morales, Jose Manuel; Choueiri, Toni K; Chin Heng, Daniel Yick; Mittal, Abhenil; Hansen, Aaron R; Rose, Brent S; McKay, Rana R.
Afiliación
  • Guram K; University of California, San Diego Health, La Jolla, California, USA.
  • Huang J; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Mouchati C; Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
  • Abdallah N; Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
  • Jani C; Mount Auburn Hospital, Harvard Medical School, Cambridge, Massachusetts, USA.
  • Navani V; University of Miami-Sylvester Comprehensive Cancer Center/Jackson Health System, Miami, Florida, USA.
  • Xie W; Tom Baker Cancer Centre, Calgary, Alberta, Canada.
  • El Zarif T; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • Adib E; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Gebrael G; Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Agarwal N; Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Li H; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
  • Labaki C; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
  • Labban M; Department of Medical Oncology, University of Kansas Cancer Center, Kansas City, Kansas, USA.
  • Ruiz Morales JM; Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Choueiri TK; Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Chin Heng DY; Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Mittal A; Hospital Medica Sur, Mexico City, Mexico.
  • Hansen AR; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • Rose BS; Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • McKay RR; Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Cancer ; 130(11): 2003-2013, 2024 Jun 01.
Article en En | MEDLINE | ID: mdl-38297953
ABSTRACT

BACKGROUND:

Existing data on the impact of Hispanic ethnicity on outcomes for patients with renal cell carcinoma (RCC) is mixed. The authors investigated outcomes of Hispanic and non-Hispanic White (NHW) patients with advanced RCC receiving systemic therapy at large academic cancer centers using the International Metastatic Renal Cell Carcinoma Database (IMDC).

METHODS:

Eligible patients included non-Black Hispanic and NHW patients with locally advanced or metastatic RCC initiating systemic therapy. Overall survival (OS) and time to first-line treatment failure (TTF) were calculated using the Kaplan-Meier method. The effect of ethnicity on OS and TTF were estimated by Cox regression hazard ratios (HRs).

RESULTS:

A total of 1563 patients (181 Hispanic and 1382 NHW) (mostly males [73.8%] with clear cell RCC [81.5%] treated with tyrosine kinase inhibitor [TKI] monotherapy [69.9%]) were included. IMDC risk groups were similar between groups. Hispanic patients were younger at initial diagnosis (median 57 vs. 59 years, p = .015) and less likely to have greater than one metastatic site (60.8% vs. 76.8%, p < .001) or bone metastases (23.8% vs. 33.4%, p = .009). Median OS and TTF was 38.0 months (95% confidence interval [CI], 28.1-59.2) versus 35.7 months (95% CI, 31.9-39.2) and 7.8 months (95% CI, 6.2-9.0) versus 7.5 months (95% CI, 6.9-8.1), respectively, in Hispanic versus NHW patients. In multivariable Cox regression analysis, no statistically significant differences were observed in OS (adjusted hazard ratio [HR], 1.07; 95% CI, 0.86-1.31, p = .56) or TTF (adjusted HR, 1.06; 95% CI, 0.89-1.26, p = .50).

CONCLUSIONS:

The authors did not observe statistically significant differences in OS or TTF between Hispanic and NHW patients with advanced RCC. Receiving treatment at tertiary cancer centers may mitigate observed disparities in cancer outcomes.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Hispánicos o Latinos / Neoplasias Renales Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Hispánicos o Latinos / Neoplasias Renales Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos